STRO Stock Forecast & Price Target

Sutro Biopharma is viewed favorably because its XpressCF platform is producing differentiated ADCs with clear preclinical and early clinical evidence of activity, including STRO-227’s 46% ORR in NSCLC PDX models and STRO-006’s 76% ORR versus 46% for Datroway in solid tumor mouse studies. The company’s lead asset STRO-004 has also shown partial responses in heavily pretreated patients across PDAC, HNSCC, and NSCLC, while maintaining dose-proportional exposure, a nearly seven-day half-life, and preserved DAR8 stability, supporting both efficacy and a manageable safety profile. In addition, Sutro reported a solid cash position of $164.3MM, and Astellas has advanced two iADC programs with up to $845MM in potential milestones, reinforcing platform value despite no revenue or earnings expected in the near term.

Sutro Biopharma is viewed negatively because its valuation depends heavily on unproven lead ADCs, and the greatest risk remains poorer-than-expected clinical results that could push approvals further out or eliminate them entirely. Although STRO-004 showed a 62% ORR across 97 PDX models and favorable early safety versus Tivdak benchmarks, those are preclinical signals, while 2Q26 revenue of $9.8MM fell short of $14.8MM and the company still posted a ($2.33) EPS loss. With R&D at $31.7MM, SG&A at $7.8MM, and cash of $164.3MM, the company remains financially dependent on future funding and faces intense competition, regulatory uncertainty, and reimbursement risk.